BREAKOUT BOARD

[BreakoutÎnvestments]

Canaccord Genuity Reiterates a 'Buy' on Cytokinetics (CYTK); Takeaways From Meetings on the Road with Management

June 2, 2011 8:25 AM EDT

http://www.streetinsider.com/Analyst+Comments/Canaccord+Genuity+Reiterates+a+Buy+on+Cytokinetics+(CYTK)%3B+Takeaways+From+Meetings+on+the+Road+with+Management/6554659.html

Canaccord Genuity reiterates a 'Buy' on Cytokinetics (NASDAQ: CYTK), PT $6.

Canaccord analyst, Ritu Baral, says, "We see CYTK shares as inexpensive on potential of CK357/ skeletal muscle and AMGN-partnered omecamtiv/cardiac muscle programs. We think CK357 Phase 1/2 proof of concept data in ALS and other muscle-wasting diseases show great potential. Further, we think CYTK’s omecamtiv partner Amgen is serious about developing omecamtiv for heart failure."

For more ratings news on Cytokinetics click here and for the rating history of Cytokinetics click here.

Shares of Cytokinetics closed at $1.37 yesterday, with a 52 week range of $1.20-$3.00.